Trials / Completed
CompletedNCT03564665
Investigating Magnesium Glycinate in Structure/Function Role of Hot Flashes.
A Randomized, Placebo Controlled, Single Blinded Trial of 400mg of Magnesium Glycinate BID Investigating the Body's Structure/Function Role of Hot Flashes.
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 40 (actual)
- Sponsor
- Mayo Clinic · Academic / Other
- Sex
- Female
- Age
- 25 Years – 85 Years
- Healthy volunteers
- Not accepted
Summary
The goal of this study is to further evaluate the effect of magnesium on the symptoms of menopause, specifically vasomotor symptoms (VMS) in breast cancer patients and/or women at an elevated risk of breast cancer.
Detailed description
Hot flashes are one of the most common symptoms that are experienced in women during perimenopause, menopause, and as a result of treatment of cancer such as breast cancer. Hot flashes, also known as vasomotor symptoms (VMS) may decrease a woman's quality of life due to discomfort, disruption of daily life, interruption of sleep, and worsening of depression. Previously, estrogen-based therapy was the primary treatment choice for VMS. However, in recent years, this has been considered less favorable due to the increased risk of breast cancer associated with estrogen-based therapy. While medications such as certain antidepressants, gabapentin and clonidine are available as non-hormonal treatment options, they appear to be less effective in comparison to estrogen therapy with reported adverse effects. Magnesium supplementation has been found to have very promising results in alleviating VMS in patients with a history of breast cancer. The goal of this study is to further investigate the effects of administering magnesium supplementation in reducing the effects of hot flashes in this targeted population. Our aim is to create a controlled trial using different dosages of magnesium glycinate in the management of hot flashes. Participants will be asked to complete surveys for data collection and analysis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIETARY_SUPPLEMENT | 400mg Magnesium Glycinate BID | 400mg Magnesium Glycinate BID for 8 weeks. |
| OTHER | Placebo | Placebo BID for 8 weeks. |
Timeline
- Start date
- 2018-07-24
- Primary completion
- 2021-04-10
- Completion
- 2021-04-10
- First posted
- 2018-06-21
- Last updated
- 2021-04-12
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT03564665. Inclusion in this directory is not an endorsement.